OnKure Therapeutics president and CEO Saccomano sells $258 in stock

Nicholas A. Saccomano, president and CEO of OnKure Therapeutics, sold 87 shares of the company's Class A Common Stock on September 21, 2026. The transaction, an automatic process to cover tax obligations related to the vesting of restricted stock units under the company's 2023 RSU Equity Incentive Plan, took place at prices between $2.95 and $3.06 per share, with a weighted average sale price of $2.9742.

This sale, totaling $258, occurred as the stock was trading at $2.90, down 27% over the past six months. Despite this decline, InvestingPro analysts suggest the company is undervalued at current levels. Following the sale, Saccomano remains a beneficial owner of 11,160 shares of OnKure Therapeutics, Inc. Class A Common Stock, with certain of these securities being RSUs.

H.C. Wainwright recently adjusted its price target for OnKure Therapeutics Inc. to $21, down from $27, while maintaining a Buy rating. This change followed preclinical data presentation for OnKure's pan-mutant PI3Kα inhibitors, OKI-345 and OKI-355, which showed significant cellular selectivity compared to competitors. These developments are part of OnKure's ongoing efforts to advance its therapeutic offerings, and investors may find these updates relevant as they assess the company's future potential.